AU782435B2 - Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain - Google Patents

Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain Download PDF

Info

Publication number
AU782435B2
AU782435B2 AU68279/00A AU6827900A AU782435B2 AU 782435 B2 AU782435 B2 AU 782435B2 AU 68279/00 A AU68279/00 A AU 68279/00A AU 6827900 A AU6827900 A AU 6827900A AU 782435 B2 AU782435 B2 AU 782435B2
Authority
AU
Australia
Prior art keywords
dihydropyrrol
general formula
radical
substituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU68279/00A
Other languages
English (en)
Other versions
AU6827900A (en
Inventor
Hermann Poschenrieder
Michael Przewosny
Hans-Dietrich Stachel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of AU6827900A publication Critical patent/AU6827900A/en
Application granted granted Critical
Publication of AU782435B2 publication Critical patent/AU782435B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
AU68279/00A 1999-08-06 2000-07-25 Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain Ceased AU782435B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19936719A DE19936719A1 (de) 1999-08-06 1999-08-06 Substituierte 1,5-Dihydropyrrol-2-on-Derivate
DE19936719 1999-08-06
PCT/EP2000/007100 WO2001010833A1 (de) 1999-08-06 2000-07-25 Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen

Publications (2)

Publication Number Publication Date
AU6827900A AU6827900A (en) 2001-03-05
AU782435B2 true AU782435B2 (en) 2005-07-28

Family

ID=7917172

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68279/00A Ceased AU782435B2 (en) 1999-08-06 2000-07-25 Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain

Country Status (25)

Country Link
US (1) US6642267B2 (sk)
EP (1) EP1200402B1 (sk)
JP (1) JP2003506437A (sk)
KR (1) KR20020025214A (sk)
CN (1) CN1378532A (sk)
AR (1) AR028848A1 (sk)
AT (1) ATE304530T1 (sk)
AU (1) AU782435B2 (sk)
BR (1) BR0013311A (sk)
CA (1) CA2381033A1 (sk)
CO (1) CO5200758A1 (sk)
CZ (1) CZ2002441A3 (sk)
DE (2) DE19936719A1 (sk)
ES (1) ES2248104T3 (sk)
HK (1) HK1046405A1 (sk)
HU (1) HUP0201937A3 (sk)
IL (1) IL147977A0 (sk)
MX (1) MXPA02001212A (sk)
NO (1) NO20020574L (sk)
NZ (1) NZ516988A (sk)
PE (1) PE20010402A1 (sk)
PL (1) PL353854A1 (sk)
SK (1) SK1702002A3 (sk)
WO (1) WO2001010833A1 (sk)
ZA (1) ZA200201788B (sk)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
CA2590997A1 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer`s disease
EP1928405B1 (en) 2005-09-28 2014-09-24 Auris Medical AG Pharmaceutical compositions for the treatment of inner ear disorders
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
NZ579310A (en) 2007-03-01 2012-03-30 Probiodrug Ag Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
KR101729340B1 (ko) * 2008-08-12 2017-04-24 진판델 파마슈티컬스 인코포레이티드 질환 위험 인자의 식별 방법
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
BR112012022478B1 (pt) 2010-03-10 2021-09-21 Probiodrug Ag Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US9102666B2 (en) 2011-01-10 2015-08-11 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating Alzheimer's disease
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
KR102084185B1 (ko) 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
US10708389B2 (en) * 2016-12-06 2020-07-07 Intelligrated Headquarters, Llc Phased deployment of scalable real time web applications for material handling system
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2170498A (en) * 1985-02-04 1986-08-06 Ici Plc Processes for making fungicidal dithiolopyrrolones

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL258360A (sk) * 1960-11-25
DE3434562A1 (de) * 1984-09-20 1986-03-27 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von pyrrothinderivaten
GB2173499A (en) * 1985-02-04 1986-10-15 Ici Plc Fungicidal dithiolopyrrolones
GB9210393D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2170498A (en) * 1985-02-04 1986-08-06 Ici Plc Processes for making fungicidal dithiolopyrrolones

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCH PHARM PHARM MED CHEM 332, 309-316 (1999) *
CHEMICAL ABSTRACTS ACCESSION NO.59:35560,RN 91558-95-1 *

Also Published As

Publication number Publication date
HK1046405A1 (zh) 2003-01-10
KR20020025214A (ko) 2002-04-03
NO20020574D0 (no) 2002-02-05
HUP0201937A3 (en) 2002-12-28
CA2381033A1 (en) 2001-02-15
AU6827900A (en) 2001-03-05
WO2001010833A1 (de) 2001-02-15
ATE304530T1 (de) 2005-09-15
DE50011178D1 (de) 2005-10-20
JP2003506437A (ja) 2003-02-18
BR0013311A (pt) 2003-01-28
US20020161033A1 (en) 2002-10-31
DE19936719A1 (de) 2001-02-15
ES2248104T3 (es) 2006-03-16
ZA200201788B (en) 2003-08-27
CZ2002441A3 (cs) 2002-05-15
EP1200402A1 (de) 2002-05-02
PE20010402A1 (es) 2001-05-05
PL353854A1 (en) 2003-12-01
MXPA02001212A (es) 2002-07-02
CN1378532A (zh) 2002-11-06
CO5200758A1 (es) 2002-09-27
US6642267B2 (en) 2003-11-04
NZ516988A (en) 2004-11-26
SK1702002A3 (en) 2002-07-02
IL147977A0 (en) 2002-09-12
EP1200402B1 (de) 2005-09-14
NO20020574L (no) 2002-03-25
HUP0201937A2 (en) 2002-10-28
AR028848A1 (es) 2003-05-28

Similar Documents

Publication Publication Date Title
AU782435B2 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as NMDA receptor antagonists for the treatment of pain
TW200950779A (en) Novel glucagon receptor antagonists, compositions, and methods for their use
MXPA06011829A (es) Derivados de 1-amino-ftalazina, su preparacion, y su aplicacion terapeutica.
AU779187B2 (en) Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as NMDA-receptor antagonists
US20030087926A1 (en) Substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid derivatives
IL101589A (en) 1 -) Pyrido] B-3,4 [- 1, 4 - Oxazine - 4 - Il (H1 - Indoles, process for their preparation and use in drugs
DE10236910A1 (de) Substituierte 1,2,3,4-Tetrahydrochinolinderivate
DE2409262A1 (de) Imidazo eckige klammer auf 1,2-a eckige klammer zu azacycloalkane
EP1751101B1 (de) Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US20040224969A1 (en) Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds
DE10137487A1 (de) Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
CN101885721A (zh) 作为ccr5拮抗剂的吡咯衍生物、制备该化合物的方法及其应用
DE102005014628A1 (de) Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
CS271297B1 (en) 1-/bicyclo/2,2,1/hept-5-en-2, 3-dicarboximido/2, 6-diethylbenzene
JP2009528316A (ja) シグマ受容体化合物